UT Health San Antonio is launching a multi-phase rapamycin program that moves from youthful biomarker benchmarking into dose-finding and then an 84-person randomized trial comparing daily dosing, intermittent dosing, and placebo in older adults. For longevity medicine, that matters more than another mouse paper because it targets the actual unanswered question: what human exposure gives mTOR benefit without tipping into immunosuppression or hyperglycemia.
8 April 2026
Longevity research worth your time, in language you can actually use.
Each morning we read the new papers on reprogramming, senolytics, gene therapy, and epigenetic clocks. Then we write you a short, honest briefing — no jargon walls, no hype.
The daily highlight is free. The full digest is $12/mo or $99/yr.
Today's highlight
7 more in today's digest
Two ways to read
Start free, upgrade when you want the whole picture.
Best value
Member
$99/yr
or $12/month
- Every paper, every morning
- Relevance scoring per paper
- Searchable archive
- Focus areas: reprogramming, gene therapy, senolytics